LAKE OSWEGO, Ore., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the appointment of David A. Scheinberg, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).
